Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Quattro74on Dec 25, 2019 11:06am

117 Views

Post# 30489800

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Light Reading for the Holidays

Ha, That will be some interview when some media group finds the 'Magic Patient' and has them compare the two treatments.

Hempdoc wrote:

Quattro74 wrote:

Hempdoc wrote:

In the FDA document, it's also unfortunate TLD 1433 got categorized as a "systemic" therapy. It was "coded" as an "unspecified" study drug...so why designate it as a systemic therapy in their summary table. Come on FDA, you know better...or at least you will soon.

Interesting Doc,

By Systemic you/they mean interstitial vs intravesical? So yeah FDA got that wrong. One of the knocks on Keytruda in that article was its systemic toxicity. I think it will need to be bought to FDAs attention that 1433 is neither 'systemic' or 'toxic' compated to Keytruda. We are talking orders of magnitude here!

Yep...intravesical delivery is very different from systemic delivery, which in regards to treating cancer, generally means delivering the drug either intravenously or via injection. Keytruda's lackluster CR durability data fell well short of expectations, & the content/tone of the FDA's summary conclusion IMO points to a significant delay in its approval (at best). My guess is it doesn't get approved, & Theralase's Ph 2 trial results (& couldn't be any better timing) will now be sharing center stage. If Theralase can produce positive CR results in a relatively small sample of patients, this would certainly exert some influence (at least indirectly) on the FDA's decision-making re: "any" experimental therapy that demonsttrates equivocal/borderline results...as is the case currently with Keytruda.